Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sangamo Therapeutics (SGMO) Tax Provisions (2016 - 2025)

Historic Tax Provisions for Sangamo Therapeutics (SGMO) over the last 8 years, with Q3 2025 value amounting to -$161000.0.

  • Sangamo Therapeutics' Tax Provisions fell 28295.45% to -$161000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$442000.0, marking a year-over-year decrease of 358333.33%. This contributed to the annual value of -$167000.0 for FY2024, which is 9670.74% up from last year.
  • Sangamo Therapeutics' Tax Provisions amounted to -$161000.0 in Q3 2025, which was down 28295.45% from $27000.0 recorded in Q2 2025.
  • Sangamo Therapeutics' 5-year Tax Provisions high stood at $1.3 million for Q3 2023, and its period low was -$6.3 million during Q2 2023.
  • Its 5-year average for Tax Provisions is -$237947.4, with a median of $82000.0 in 2022.
  • Within the past 5 years, the most significant YoY rise in Sangamo Therapeutics' Tax Provisions was 413333.33% (2023), while the steepest drop was 773902.44% (2023).
  • Quarter analysis of 5 years shows Sangamo Therapeutics' Tax Provisions stood at -$94000.0 in 2021, then skyrocketed by 343.62% to $229000.0 in 2022, then crashed by 218.78% to -$272000.0 in 2023, then tumbled by 56.99% to -$427000.0 in 2024, then skyrocketed by 62.3% to -$161000.0 in 2025.
  • Its Tax Provisions was -$161000.0 in Q3 2025, compared to $27000.0 in Q2 2025 and $119000.0 in Q1 2025.